How to Choose an FDA Pathway for Medical Devices
Last Updated: November 5, 2026
Quick Summary
Choosing an FDA pathway starts with classifying your device as Class I, Class II, or Class III, since risk level and controls point to the expected submission type. Low to moderate risk with a valid predicate supports 510(k), no valid predicate supports De Novo, and high risk requires PMA.
Check the FDA classification regulation first for the class, regulation number, and expected submission type.
A 510(k) requires substantial equivalence to a legally marketed predicate with the same intended use.
De Novo classification suits novel low to moderate risk devices with no valid predicate and needs proposed special controls.
PMA requires standalone safety and effectiveness evidence, with no predicate shortcut for Class III devices.
Request an FDA pre-submission meeting for borderline or combination products before committing to a pathway.
Table of Contents
Start With FDA Medical Device Classification
FDA pathway selection for medical devices starts with one question: how much risk does your device pose? The answer decides almost everything that follows.
Classification is not a formality. It sets the controls you must meet, and those controls point to a specific premarket submission.
The FDA sorts devices into three classes. Each class carries a different level of regulatory control.
Class I, Class II, and Class III Risk Levels
Class I covers low-risk devices. Most are exempt from premarket review, though general controls still apply.
Class II covers moderate-risk devices. These usually need special controls plus a 510(k) clearance.
Class III covers high-risk devices.
The FDA publishes classification regulations for each device type. Check those first.
A common mistake is guessing the class from how new the idea feels.
General Controls and Special Controls
General controls apply to every device. They cover things like proper labeling, manufacturing practices, and reporting adverse events.
Special controls apply mostly to Class II devices. They can include performance standards, post-market surveillance, and specific labeling requirements.
The FDA treats pathway selection as a result of classification and controls, not a starting point (EXTERNAL_LINK: FDA guidance on studying and marketing a device | https://www.fda.gov/medical-devices/how-study-and-market-your-device).
Define Intended Use and Indications for Use Before You Compare Pathways
Your intended use statement drives your FDA pathway more than any other document. Write it before you compare submission types.
Both statements shape three things:
Which classification regulation applies
Which predicate devices are valid comparisons
What clinical evidence the FDA will expect
A vague intended use creates a vague pathway. If your statement says "monitors patient health," the FDA cannot classify it cleanly.
Watch out: broadening your indications to capture a bigger market can push the device into a higher class and a longer review.
The Types of FDA Submissions for Medical Devices
Three premarket submissions cover most devices: 510(k), De Novo, and PMA. Each matches a different risk level and evidence burden.
Here is how they compare at a glance:
Submission | Device Risk | Core Test | Typical Use |
510(k) | Low to moderate | Substantial equivalence to a predicate | Class II devices with a valid comparison |
De Novo | Novel, low to moderate | No valid predicate exists | New device types with no legally marketed comparison |
PMA | High | Standalone safety and effectiveness evidence | Class III devices |
Supporting documents for any of these will need testing evidence, including biocompatibility data where the device contacts the body. We cover what that testing involves in our guide to medical device biocompatibility testing requirements.
510(k) vs. De Novo vs. PMA: How the Three Pathways Differ
The three pathways differ in one fundamental way: whether you can lean on an existing device. That single fact decides your evidence strategy.
510(k) Premarket Notification and Substantial Equivalence
The 510(k) is a premarket notification. You show your device is substantially equivalent to a legally marketed device, called a predicate.
The FDA requires applicants to compare their device with one or more similar legally marketed devices and to support the equivalence claims (EXTERNAL_LINK: FDA on the pathway to approval | https://www.fda.gov/medical-devices/how-study-and-market-your-device/step-3-pathway-approval).
A strong 510(k) rests on three things:
A well-chosen predicate with the same intended use
Clear comparison tables covering technology and performance
Bench or clinical data that explain any differences
Differences in technology are acceptable if they do not raise new questions about safety and effectiveness. That is the whole argument.
De Novo Classification for Novel Devices
De Novo classification is for novel devices with low to moderate risk and no valid predicate.
De Novo requests need two things: evidence that the device is safe and effective, and a proposal for special controls that will manage its risks.
This pathway rewards early planning. The special controls you propose become the rules every later device in your category must meet.
A 2022 review of device translation identified people, processes, and product selection as the three critical elements for success, and stressed flexibility when weighing evidence requirements (review of the FDA Breakthrough Devices Program(https://pmc.ncbi.nlm.nih.gov/articles/PMC8920055/)). That flexibility matters most in De Novo work, where you are partly writing the rules.
Premarket Approval for High-Risk Devices
PMA is the most demanding path. It requires valid scientific evidence that the device is safe and effective for its intended use.
There is no predicate shortcut here. You submit clinical data, manufacturing information, and nonclinical testing as a standalone package.
The FDA's Breakthrough Devices Program offers a faster review track for eligible devices. As of June 30, 2026, the agency reported 210 marketing authorizations under the program, including 205 from CDRH and five from CBER (FDA Breakthrough Devices Program(https://www.fda.gov/medical-devices/how-study-and-market-your-device/breakthrough-devices-program)).
A Practical Decision Tree for FDA Pathway Selection
Use this sequence to narrow your options. Work through it in order and stop at the first clear answer. The criteria below turn broad pathway descriptions into a repeatable selection process.
Find your classification regulation. Start with the FDA's device classification database. Note the class, regulation number, and the submission type the regulation expects. If no regulation matches your device, that is a signal you may be in De Novo territory.
Draft your intended use and indications. Keep them narrow and specific. The intended use must state the function, the patient population, and the care setting. Vague claims make every later step unreliable.
Search for a valid predicate. Look for a legally marketed device with the same intended use. A predicate with a different intended use is not a valid comparison, even if the technology looks similar.
Test substantial equivalence. If a predicate exists, compare technology, performance, and labeling. Differences are acceptable only if they do not raise new questions about safety and effectiveness. If you cannot support that argument, a 510(k) is the wrong path.
If no valid predicate exists and risk is low to moderate, pursue De Novo classification. You will need safety and effectiveness evidence plus a proposed special controls framework.
If the device is Class III or sustains life, plan for PMA. There is no predicate shortcut.
If the device is borderline or combines drug and device elements, request a pre-submission meeting with the FDA before committing. Do not assume every product fits a standard device pathway.

Explicit Selection Criteria
Four factors drive the decision. Score your device against each before you commit.
Risk level: Class I, II, or III. This sets the controls and narrows the submission type.
Intended use: The function, population, and setting. This determines which regulation applies and which predicates are valid.
Novelty: Whether a legally marketed comparison exists. No predicate points to De Novo or PMA.
If risk is low to moderate and a valid predicate exists with supportable equivalence, the 510(k) is the likely path. If risk is low to moderate and no valid predicate exists, De Novo is the likely path. If risk is high, PMA is the likely path regardless of predicate availability.
Borderline and Combination-Product Cases
Not every product fits a standard device pathway. A product that combines a drug and a device, or one whose jurisdiction is unclear, needs an FDA determination before you plan a submission. The FDA's pre-submission process is the mechanism for that. Request a meeting, present your intended use and preliminary data, and ask the agency to confirm the pathway.
What Happens When You Choose Wrong
A mismatched pathway is not a minor delay. A 510(k) built on an invalid predicate will be rejected, and you will restart with De Novo or PMA evidence requirements. A De Novo request for a device that actually has a valid predicate wastes the special-controls work. A PMA-track device submitted as a 510(k) will not clear. The cost is measured in months of rework and duplicated testing, not just filing effort.
FDA Medical Device Approval Process Timeline and Evidence Planning
Timelines vary widely by pathway and device. Plan your evidence before you plan your calendar, because evidence generation is usually the longest pole.
Evidence Planning by Pathway
Evidence needs depend on the device and its claims, but the pattern by pathway looks like this:
510(k): bench testing, comparison data against the predicate, and sometimes clinical data for new technologies. Biocompatibility testing is needed where the device contacts the body. Software and cybersecurity documentation are needed for devices with software.
De Novo: performance testing plus a proposed special controls framework. You are partly writing the rules future devices in your category will follow, so the evidence must justify those controls.
PMA: full nonclinical and clinical studies, plus manufacturing validation. There is no predicate shortcut, so the evidence package stands alone.
A common pattern is that teams underestimate software and cybersecurity evidence. If your device has software, plan for that documentation early rather than treating it as a final step.
Realistic Timeline Factors
Review timelines depend on the pathway, the completeness of your submission, and whether the FDA raises additional questions. Rather than quote a single number, plan around the factors that change review effort:
Pathway: PMA review is longer and more iterative than 510(k) review. De Novo sits between them and includes special-controls negotiation.
Evidence burden: Clinical studies add the most time. Bench-only submissions move faster.
Submission quality: An incomplete submission triggers additional-information requests, which extend the review.
The FDA's Total Product Life Cycle Advisory Program gives sponsors earlier feedback across the review life cycle. As of October 7, 2026, 159 devices were enrolled in the pilot, and the agency expanded enrollment on July 1, 2026 (FDA TAP program(https://www.fda.gov/medical-devices/how-study-and-market-your-device/total-product-life-cycle-advisory-program-tap)).
Resource Planning
Budget for testing early. Development work tied to evidence generation may qualify for the R&D tax credit. Confirm eligibility with a tax professional. Staff time for regulatory correspondence, testing coordination, and submission assembly is often underestimated.
Watch out: building a timeline from the FDA's review goal alone ignores the months of evidence generation that precede submission. Plan backward from the evidence, not forward from the filing date.
Common Pathway-Selection Mistakes and How Design Decisions Affect Them
Most pathway problems start in design, not in paperwork. Here are the mistakes we see most often.
Choosing a pathway before classification. Class and controls come first.
Picking a weak predicate. A shaky comparison sinks the whole submission.
Overstating intended use. Broader claims pull in higher risk and more evidence.
Design decisions carry regulatory weight. A material change can trigger new biocompatibility testing. A housing redesign can invalidate prior performance data. Getting mechanical engineering input early keeps those choices from forcing a resubmission. Our mechanical engineering team works through design and prototyping with these constraints in view.
Bring Your Device Concept to 2B Studio
Pathway planning only pays off if the product itself can be built, tested, and documented to match.
At 2B Studio, we take product concepts through design-driven product development, balancing manufacturing requirements, user experience, and marketplace demands.
Turn your medical device idea into a market-ready product, or review our plans and pricing to see how an engagement fits your budget.
Frequently Asked Questions
How do you choose between 510(k), De Novo, and PMA?
Start with classification. If a legally marketed predicate device exists and you can support substantial equivalence, a 510(k) is usually the route. If your device is novel with no valid predicate but is low to moderate risk, a De Novo request can create a new classification. If the device is high risk (Class III), Premarket Approval is generally required. FDA guidance ties pathway selection to classification and applicable regulatory controls, so document your reasoning before you draft a submission.
How does FDA device classification affect the submission pathway?
Classification sets the regulatory controls your device must meet, and those controls determine which submission type applies. Class I devices are generally subject to general controls, Class II devices often need special controls plus a 510(k), and Class III devices typically require PMA. FDA frames pathway selection as dependent on classification, so confirm your class and product code before planning evidence or timelines.
What evidence is needed for a De Novo request or PMA?
A De Novo request must show the device is low to moderate risk and include data supporting safety and effectiveness, plus proposed special controls. A PMA requires valid scientific evidence, typically including clinical data, to demonstrate safety and effectiveness for the intended use. Both depend on a clear intended use and indications for use. Plan performance testing and clinical evidence early, because these requirements shape device development long before submission.
When does a medical device need a 510(k) submission?
A 510(k) is generally needed when your device is Class II or otherwise requires premarket notification and you can identify one or more legally marketed predicate devices. FDA expects you to compare your device with the predicate and support your substantial-equivalence claims rather than assume them. If no suitable predicate exists, or if the comparison fails, evaluate De Novo or PMA instead. Confirm requirements for your specific device type before committing.
The hardest part of FDA pathway selection is not reading the regulations. It is designing a device that meets them without losing the product you set out to build. 2B Studio brings industrial design, prototyping, and manufacturing know-how to that challenge, so your device is ready for testing and review from the start. Get started with 2B Studio and turn your concept into a product that is ready for the market.





Comments